Author

Tracy A. Cole

Ionis Pharmaceuticals (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

Alix BoomsiD· 1 shared Allyson Cole-Strauss· 1 shared Andreas WeihofeniD· 1 shared Andy Watt· 1 shared Apoorva Mohan· 1 shared Berit E. PowersiD· 1 shared Brian F. Daley· 1 shared C. Frank BennettiD· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Alix BoomsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genotypic and phenotypic analysis of 173 patients with extremely rare pathogenic mutations who applied for experimental antisense oligonucleotide treatment

Stanley T. Crooke, Tracy A. Cole, Jeffrey B. Carroll, Joseph G. Gleeson, Laurence Mignon, Julie Douville, Wendy K. Chung, Jennifer Bain, Elizabeth Berry‐Kravis, Nelson Leung, Andy Watt, Berit E. Powers, Cedrik Tekendo‐Ngongang, Stanislav Kmoch, Petr Vyleťal, Sarah Glass

The paper analyzes genotypic and phenotypic data from 173 patients with nano-rare mutations to explore genotype-phenotype relationships and the potential for antisense oligonucleotide therapy.

medRxiv · Aug 5, 2024 · PreprintGenetic & Genomic Medicine

Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

Tracy A. Cole, Hien Tran Zhao, Timothy J. Collier, Ivette M. Sandoval, Caryl E. Sortwell, Kathy Steece‐Collier, Brian F. Daley, Alix Booms, Jack W. Lipton, Mackenzie Welch, Melissa Berman, Luke Jandreski, Danielle L. Graham, Andreas Weihofen, Stephanie L. Celano, , Katrina L. Paumier

This paper demonstrates that antisense oligonucleotides targeting SNCA reduce alpha-synuclein production, prevent pathology, and show translational potential in non-human primates.

bioRxiv · Nov 4, 2019 · PreprintNeuroscience